JAGX
No price yet
Announcements
Nothing here yet
Daily updates
- Jaguar Health reported continued progress for crofelemer in rare intestinal disorders, with pediatric MVID and SBS-IF studies showing reduced parenteral support requirements and favorable one-year safety.Oct 6, 2026
- Jaguar Health’s early clinical findings from an ongoing open-label crofelemer trial in adults with short bowel syndrome and intestinal failure were accepted for presentation at ACG 2026 on October 9–14.Sep 29, 2026
- Jaguar Health secured FDA user fee waivers for FY2027 covering Mytesi and Canalevia-CA1, reducing upcoming regulatory expenses while advancing crofelemer for rare intestinal disorders.Sep 22, 2026
- Jaguar expanded compassionate use of oral crofelemer for congenital sodium diarrheaSep 7, 2026
FDA designations
Nothing here yet
News
- Jaguar Health announced plans to explore strategic alternatives aligned with its rare disease intestinal failure programJun 23, 2026
- Jaguar Health announced preliminary discussions with the FDA to evaluate Breakthrough Therapy designation for crofelemer in MVIDMay 6, 2026
- Jaguar Health reported statistically significant results from the Crofelemer effectiveness trial for chemotherapy-induced diarrhea in dogsApr 29, 2026
- Jaguar Health completed effectiveness trial supporting crofelemer use for chemotherapy-induced diarrhea in dogsApr 8, 2026
- FDA-authorized expanded access programs utilize Jaguar Health's novel Crofelemer powder oral solution to treat two pediatric intestinal failure patients with microvillus inclusion diseaseSep 30, 2025